Last reviewed · How we verify
insulin glargine and insulin aspart
insulin glargine and insulin aspart is a Small molecule drug developed by Dr. Muhammad Abdulghani. It is currently in Phase 1 development. Also known as: lantus.
At a glance
| Generic name | insulin glargine and insulin aspart |
|---|---|
| Also known as | lantus |
| Sponsor | Dr. Muhammad Abdulghani |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (PHASE3)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (PHASE3)
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin glargine and insulin aspart CI brief — competitive landscape report
- insulin glargine and insulin aspart updates RSS · CI watch RSS
- Dr. Muhammad Abdulghani portfolio CI
Frequently asked questions about insulin glargine and insulin aspart
What is insulin glargine and insulin aspart?
insulin glargine and insulin aspart is a Small molecule drug developed by Dr. Muhammad Abdulghani.
Who makes insulin glargine and insulin aspart?
insulin glargine and insulin aspart is developed by Dr. Muhammad Abdulghani (see full Dr. Muhammad Abdulghani pipeline at /company/dr-muhammad-abdulghani).
Is insulin glargine and insulin aspart also known as anything else?
insulin glargine and insulin aspart is also known as lantus.
What development phase is insulin glargine and insulin aspart in?
insulin glargine and insulin aspart is in Phase 1.
Related
- Manufacturer: Dr. Muhammad Abdulghani — full pipeline
- Also known as: lantus
- Compare: insulin glargine and insulin aspart vs similar drugs
- Pricing: insulin glargine and insulin aspart cost, discount & access